[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kras-pg12c\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kras-pg12c":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,72,99,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100469844","phase-2-clinical-trial-of-amg510-in-stage-iii-unresectable-nsclc-kras-pg12c-patients-and-ineligible-for-chemo-radiotherapy-100469844",false,"NCT05398094","Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy","Phase II Clinical Trial of AMG510 (Sotorasib) in Stage III Unresectable NSCLC KRAS p.G12C Patients and Medically Ineligible for Concurrent Chemo-radiotherapy","MERIT-lung","Inclusion Criteria:\n\n* 1\\. Male or female, aged ≤ 80 years old\n* 2\\. ECOG performance status of 0-1\n* 3\\. Histologically or cytologically confirmed, unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology.\n* 4\\. Patients who have documentation of KRAS p.G12C prior to enrollment. This determination can be done either by solid or liquid biopsy.\n* 5\\. No prior treatment for unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC.\n* 6\\. Having a life expectancy ≥ 12 weeks\n* 7\\. Patients must be ineligible for concurrent chemo-radiotherapy because of:\n\n  1. Tumor size ≥ 5 cm and lymph node N2 involvement\n  2. The target lesion has to be bulky disease and\u002For more than 35% of the total volume of the two lungs should receive more than 20 Gy (V20) or inadequate pulmonary function\n  3. Interstitial Lung diseases\n  4. Prior treatment with thoracic radiotherapy for any reason\n  5. Or under decision of a tumor committee as inappropriate due to local characteristics to perform treatment upfront\n* 8\\. PET-CT at baseline is mandatory to confirm the absence of distant disease and to confirm unresectable disease\n* 9\\. PET-CT positive mediastinic adenopathies must be histologically confirmed. Mediastinic involvement could be considered without histological test when no margin can be distinguished in the lymph node mass.\n* 10\\. Brain CT or MRI is mandatory\n* 11\\. Patients with at least 1 measurable lesion, as defined by RECIST v1.1.\n* 12\\. Adequate hematologic and organ function.\n* 13\\. All patients are notified of the investigational nature of this study and signed a written informed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention.\n* 14\\. Willingness and ability to comply with scheduled visits and study procedures\n* 15\\. For female patients of childbearing potential, a negative pregnancy test must have been documented prior to enrollment (within 14 days prior to enrollment).\n* 16\\. For female patients of childbearing potential, agreement (by patient and\u002For partner) to usea highly effective form(s) of contraception that results in a low failure rate (\\\u003C 1% per year)when used consistently and correctly, and to continue its use for 7 days after the last dose of AMG510 (Sotorasib). No hormonal methods and preferably barrier method always containing a spermicide, intrauterine device (IUD): intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.\n* 17\\. For male patients with female partners of childbearing potential, agreement (by patient and\u002For partner) to use a highly effective form(s) of contraception that results in a low failure rate \\[\\\u003C 1% per year\\] when used consistently and correctly, and to continue its use for 7 days after the last dose of AMG510 (Sotorasib).\n* 18\\. Women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to enrollment.\n* 19\\. QTc interval must be ≤ 470 msec in females and ≤ 450 msec in males, based on the average obtained from three ECG.\n\nExclusion Criteria:\n\n* 1\\. Patients with a known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene, ALK translocations or ROS1 mutations\n* 2\\. Weight loss \\>10% within the previous 3 months\n* 3\\. Patients with uncontrolled neuropathy (sensory) grade 2 or greater regardless of cause according to CTCAE v5.0\n* 4\\. Major surgery within 28 days of study day 1\n* 5\\. Significant gastrointestinal disorder that results in significant malabsorption, requirement for intravenous alimentation, or inability to take oral medication\n* 6\\. Significant cardiovascular disease, such as New York Heart Association cardiac disease (ClassII or greater), myocardial infarction within 6 months prior to study day 1, unstable arrhythmias or unstable angina\n* 7\\. Ongoing cardiac dysrhythmias of CTCAE grade ≥2, uncontrolled atrial fibrillation of any grade or QTcF interval \\> 470ms\n* 8\\. Severe infections within 4 weeks prior to randomization including, but not limited to hospitalization for complications of infection, bacteremia or severe pneumonia\n* 9\\. Therapeutic oral or intravenous antibiotics within 2 weeks prior to randomization\n* 10\\. Patients with any concomitant and uncontrolled medical disorder\n* 11\\. Patients with vena cava syndrome\n* 12\\. Malignant pleural or pericardial effusion: both will be considered as suggestive of metastaticdisease. Also, are excluded those with negative cytology but being exudates. Patients with non-visible by thoracic X-ray pleural effusion or too small to be safely punctured could be included.\n* 13\\. Prior treatment with anti-neoplasic drugs\n* 14\\. Malignancies other than NSCLC within 3 years prior to enrollment\n* 15\\. Women who are pregnant, lactating, or intending to become pregnant during the study.\n* 16\\. Positive test for HIV. All patients will be tested for HIV prior to inclusion into the study; patients who test positive for HIV will be excluded from the clinical study.\n* 17\\. Patients with active hepatitis B or hepatitis C.\n* 18\\. Active tuberculosis.\n* 19\\. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.\n* 20\\. Patients with illnesses or conditions that interfere with their capacity to understand follow and\u002For comply with study procedures.\n* 21\\. Known or suspected hypersensitivity to drugs with similar chemical structures to the study drug\n* 22\\. Evidence of any other disorder or significant laboratory finding that makes the patient undesirable to participate in the study\n* 23\\. Use of strong inducers of CYP3A4 within 14 days of half-lives (whichever is longer) prior to study day 1\n* 24\\. Use of proton pump inhibitors within 14 days to study day","ALL","18 Years",{"count":20,"type":21},19,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Open-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of induction treatment of AMG510 (Sotorasib) plus AMG510 (Sotorasib) treatment post-induction as measured by Progression Free Survival at 12 months.",[27,28],"Non-small Cell Lung Cancer Stage III","KRAS P.G12C",[30,31,32,33],"Sotorasib","Unresectable","Chemo-radiotherapy","Lung cancer","RECRUITING","2026-04-29",{"date":37,"type":38},"2026-04-30","ACTUAL",{"date":40,"type":38},"2022-03-21",{"date":42,"type":21},"2028-12-31",{"name":44,"class":45},"Fundación GECP","OTHER",20,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100516727","phase-2-a-phase-ii-study-evaluating-jab-21822-monotherapy-in-adult-patients-with-pancreatic-cancer-and-other-solid-tumors-harboring-the-kras-pg12c-mutation-100516727","NCT06008288","A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","A Single-arm, Multicenter, Open-label Phase II Clinical Study Evaluating the Efficacy and Safety of JAB-21822 Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","Inclusion Criteria:\n\n* Patients with the KRAS p.G12C mutation confirmed through testing using prospectively validated companion diagnostic reagents or clinical trial assay (CTA) methods.\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors (excluding NSCLC and CRC).\n* Patients with pancreatic cancer must have progressed or been intolerant to prior gemcitabine-based chemotherapy regimens or FOLFIRINOX\u002FmFOLFIRINOX\u002FNALIRIFOX treatment. Patients with other types of solid tumors must have progressed or been intolerant to prior systemic therapies and lack satisfactory alternative treatment options.\n\nExclusion Criteria:\n\n* Previously received a KRAS G12C inhibitor.\n* History of interstitial lung disease, non-infectious pneumonia, or uncontrolled lung disease (including pulmonary fibrosis, acute lung disease, etc.) with clinical symptoms.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites.\n* Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 electrocardiograms.\n* Use of a drug with known risk of torsades de points (TdP) within 14 days prior to the first dose.",{"count":55,"type":21},88,[24],"Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.",[28,59,60],"Pancreatic Cancer","Solid Tumor","2026-03-11",{"date":63,"type":38},"2026-03-13",{"date":65,"type":38},"2023-10-27",{"date":67,"type":21},"2027-12-31",{"name":69,"class":70},"Allist Pharmaceuticals, Inc.","INDUSTRY",31,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100470767","phase-1-a-study-of-d3s-001-monotherapy-or-combination-therapy-in-subjects-with-advanced-solid-tumors-with-a-kras-pg12c-mutation-100470767","NCT05410145","A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","A Phase 1\u002F2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","Inclusion:\n\n* Subject must have a histologically or cytologically confirmed metastatic or locally advanced solid tumor which is progressing.\n* Subject must have documented KRAS p.G12C mutation identified within the last 5 years by a local test on tumor tissue or blood.\n* Subject must have measurable disease per RECIST v1.1.\n* Subject must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Subject must have adequate organ and marrow function within the screening period.\n\nExclusion:\n\n* Subject has any prior treatment with other treatments without adequate washout periods as defined in the protocol.\n* Subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.\n* Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade ≥2 (with exception of vitiligo or alopecia).\n* Subject has active gastrointestinal disease or other that could interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.\n* Concurrent participation in any clinical research study involving treatment with any investigational drug, radiotherapy, or surgery, except for the nontreatment phases of these studies (e.g., follow-up phase).\n\nOther protocol inclusion\u002Fexclusion criteria may apply",{"count":80,"type":21},442,[82,24],"PHASE1","This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1\u002F2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.",[28],[86,87,88],"KRAS p.G12C","Mutation","advanced solid tumors","2026-03-10",{"date":91,"type":38},"2026-03-12",{"date":93,"type":38},"2022-08-03",{"date":95,"type":21},"2027-04",{"name":97,"class":70},"D3 Bio (Wuxi) Co., Ltd",52,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":5},"100487758","phase-2-sotorasib-in-previously-treated-locally-advanced-or-metastatic-nsclc-subjects-with-mutated-kras-pg12c-100487758","NCT05631249","Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C","An Interventional and Translational Study Investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C","CODEBREAK-IGR","Inclusion Criteria:\n\n* Age higher than 18 years;\n* ECOG less or equal to 1 at the time of screening;\n* Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through molecular testing (results of both tissue and liquid biopsy are accepted);\n* Subjects will have progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and unresectable or metastatic disease.\n* Life expectancy of longer than 3 months from the time of screening, in the opinion of the investigator;\n* Patients must have lesions easily accessible to biopsy and must have accepted to perform pre-treatment, on-treatment and end-of-treatment biopsies;\n* Have adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to registration\n* Patients must understand, sign and date the written informed consent from prior to any protocol-specific procedures performed.\n* Patients should be able and willing to comply with study visits and procedures as per protocol.\n* Patients must be affiliated to a Social Security System or beneficiary of the same.\n\nExclusion Criteria:\n\n* Patient unwilling to participate to the biological investigations and to perform biopsies and blood sample collection as required in the protocol;\n* Use of known cytochrome P450 (CYP) 3A4 or P-gp sensitive substrates (with a narrow therapeutic window), within 14 days or 5 half-lives of the drug or its major active metabolite, whichever is longer, prior to registration, that was not reviewed and approved by the principal investigator.\n* Use of strong inducers of CYP3A4 (including herbal supplements such as St. John's wort) within 14 days or 5 half-lives (whichever is longer) prior to registration, that was not reviewed and approved by the principal investigator.\n* Inadequate washout period prior to registration, defined as: Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) from a previous cancer treatment regimen or clinical study shorter than 14 days or 5 half-lives;\n* Prior treatment with a KRAS inhibitor.\n* Major surgery within 28 days of registration.\n* Significant gastrointestinal disorder that results in significant malabsorption, requirement for intravenous alimentation, or inability to take oral medication.\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 6 months prior to registration, unstable arrhythmias or unstable angina.\n* Severe infections within 2 weeks prior to registration, but not limited to hospitalization for complications of infection, bacteremia or severe pneumonia. Prophylactic antibiotics are allowed.\n* Baseline or unresolved pneumonitis from prior treatment;\n* Current CTCAE version 5.0 grade higher or equal to 2 peripheral neuropathy.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures at a frequency greater than monthly. Subjects with PleurX catheters in place may be considered for the study with Principal Investigator approval.\n* Known history of Human Immunodeficiency Virus (HIV) infection\n* Exclusion of hepatitis infection based on the following results and\u002For criteria:\n\n  1. Positive hepatitis B surface antigen (HepBsAg) (indicative of chronic Hepatitis B or recent acute hepatitis B)\n  2. Negative HepBsAg with a positive for hepatitis B core antibody (Hepatitis B core antibody testing is not required for screening, however if this is done and is positive, then hepatitis B surface antibody \\[Anti-HBs\\] testing is necessary.\n\n     Undetectable anti-HBs in this setting would suggest unclear and possible infection, and needs exclusion).\n  3. Positive Hepatitis C virus antibody: Hepatitis C virus RNA by polymerase chain reaction is necessary. Detectable Hepatitis C virus RNA renders the subject ineligible.\n* Leptomeningeal disease and active brain metastases. Subjects who have had brain metastases resected or have received whole brain radiation therapy or stereotactic radiosurgery ending at least 2 weeks prior to registration are eligible if they meet all of the following criteria:\n\n  1. residual neurological symptoms grade less or equal to 2;\n  2. on stable doses of dexamethasone or equivalent for at least 2 weeks, if applicable; and\n  3. follow-up brain imaging performed within 30 days of enrollment shows no progression or new lesions appearing.\n* Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 7 days after the last dose of sotorasib or during treatment if planning to become pregnant.\n* Female subjects of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for an additional 7 days after the last dose of sotorasib\n* Female subjects of childbearing potential with a positive pregnancy test assessed at Screening or day 1 by a serum pregnancy test and\u002For urine pregnancy test.\n* Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 7 days after the last dose of sotorasib\n* Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 7 days after the last dose of sotorasib\n* Male subjects unwilling to abstain from donating sperm during treatment and for an additional 7 days after the last dose of investigational product.\n* Any evidence of primary malignancy other than locally advanced or metastatic lung cancer at within 3 years of registration, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated;\n* Participation in another clinical trial evaluating an experimental drug (except non-interventional research).\n* Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.\n* Hypersensitivity to the active substance or to any excipient\n* Patients with hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption",{"count":108,"type":21},40,[24],"This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.",[28,112],"Non Small Cell Lung Cancer","2025-05-07",{"date":115,"type":38},"2025-05-08",{"date":117,"type":38},"2022-12-13",{"date":119,"type":21},"2027-12-12",{"name":121,"class":45},"Gustave Roussy, Cancer Campus, Grand Paris",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},"100461404","phase-1-phase-12a-study-of-jab-21822-plus-jab-3312-in-patients-with-advanced-solid-tumors-harboring-kras-pg12c-mutation-100461404","NCT05288205","Phase 1\u002F2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","A Phase 1\u002F2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","Inclusion Criteria:\n\n* A written informed consent should be signed by a subject or his\u002Fher legal representative before any study-related procedures are performed;\n* Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or intolerant to SOC;\n* Expected survival ≥ 3 months;\n* Subjects must have at least one measurable lesion as defined by RECIST v1.1. If no measurable lesion untreated with radiation is selected as the target lesion, a lesion treated with radiation ≥ 4 weeks before the first dose and with progression confirmed by radiography may be selected as the target lesion;\n* Eastern Cooperative Oncology Group(ECOG) performance status 0-1;\n* The organ functions of subjects meet the criteria for the following laboratory parameters at screening;\n* Subjects must be able to swallow oral medications without gastrointestinal abnormalities that significantly affect drug absorption\n\nExclusion Criteria:\n\n* Patients with previous (≤ 3 years) or current tumors of other pathological types, except for cured cervical carcinoma in situ, ductal carcinoma in situ of the breast, prostatic intraepithelial neoplasia, superficial non-invasive bladder cancer, stage I skin cancer (except melanoma); subjects without recurrence or metastasis for \\> 3 years after treatment, without current evidence of tumor, and without significant risk of recurrence of previous malignant diseases in the opinion of the study doctor may also be enrolled;\n* Serious allergy to the investigational drug or excipients (such as microcrystalline cellulose, etc.);\n* Patients with previous (≤ 6 months before the initiation of treatment) or current severe autoimmune diseases (including adverse reactions caused by previous anti- tumor immunotherapies), or autoimmune diseases requiring long-term systemic hormone therapy at immunosuppressive dose levels (prednisone \\> 10 mg\u002Fday or equivalent drugs);\n* HIV, hepatitis B virus(HBV), or hepatitis C virus(HCV) positive;\n* Previous (≤ 6 months prior to the first dose) or current evidence of the following diseases: acute myocardial infarction, unstable angina and cerebrovascular accident;\n* Subjects who have impaired cardiac functions or clinically significant cardiac diseases;\n* Pregnant or lactating women",{"count":130,"type":21},240,[82,24],"This is a multicenter, open-label phase 1\u002F2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.",[28,134,135,136],"Non-small Cell Lung Cancer","Colorectal Cancer","Pancreatic Ductal Carcinoma","2025-04-03",{"date":139,"type":38},"2025-04-04",{"date":141,"type":38},"2022-04-14",{"date":143,"type":21},"2026-03",{"name":69,"class":70},27]